HRP20010039B1 - Quinoline derivatives - Google Patents

Quinoline derivatives

Info

Publication number
HRP20010039B1
HRP20010039B1 HR20010039A HRP20010039A HRP20010039B1 HR P20010039 B1 HRP20010039 B1 HR P20010039B1 HR 20010039 A HR20010039 A HR 20010039A HR P20010039 A HRP20010039 A HR P20010039A HR P20010039 B1 HRP20010039 B1 HR P20010039B1
Authority
HR
Croatia
Prior art keywords
chloro
fluoro
hydrogen
ochxfy
bromo
Prior art date
Application number
HR20010039A
Other languages
English (en)
Croatian (hr)
Inventor
Bj�rk Anders
J�nsson Stig
Fex Tomas
Hedlund Gunnar
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of HRP20010039A2 publication Critical patent/HRP20010039A2/hr
Publication of HRP20010039B1 publication Critical patent/HRP20010039B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
HR20010039A 1998-07-15 2001-01-12 Quinoline derivatives HRP20010039B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802549A SE9802549D0 (sv) 1998-07-15 1998-07-15 Quinoline derivatives
PCT/SE1999/001270 WO2000003991A1 (en) 1998-07-15 1999-07-14 Quinoline derivatives

Publications (2)

Publication Number Publication Date
HRP20010039A2 HRP20010039A2 (en) 2001-12-31
HRP20010039B1 true HRP20010039B1 (en) 2009-04-30

Family

ID=20412093

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010039A HRP20010039B1 (en) 1998-07-15 2001-01-12 Quinoline derivatives

Country Status (33)

Country Link
EP (1) EP1095021B1 (zh)
JP (1) JP4045070B2 (zh)
KR (1) KR100516382B1 (zh)
CN (1) CN1157378C (zh)
AP (1) AP1366A (zh)
AT (1) ATE250036T1 (zh)
AU (1) AU751103B2 (zh)
BR (1) BR9912109B1 (zh)
CA (1) CA2336968C (zh)
CZ (1) CZ300229B6 (zh)
DE (1) DE69911415T2 (zh)
DK (1) DK1095021T3 (zh)
EE (1) EE04673B1 (zh)
ES (1) ES2205854T3 (zh)
HK (1) HK1035715A1 (zh)
HR (1) HRP20010039B1 (zh)
HU (1) HU229427B1 (zh)
ID (1) ID27423A (zh)
IL (2) IL140346A0 (zh)
IS (1) IS2208B (zh)
ME (1) ME00374B (zh)
NO (1) NO317601B1 (zh)
NZ (1) NZ508923A (zh)
OA (1) OA11906A (zh)
PL (1) PL199783B1 (zh)
PT (1) PT1095021E (zh)
RS (1) RS50128B (zh)
RU (1) RU2213733C2 (zh)
SE (1) SE9802549D0 (zh)
TR (1) TR200100087T2 (zh)
UA (1) UA64791C2 (zh)
WO (1) WO2000003991A1 (zh)
ZA (1) ZA200007593B (zh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
US6395750B1 (en) * 1999-10-25 2002-05-28 Active Biotech Ab Drugs for the treatment of malignant tumors
AU2003242127A1 (en) * 2002-06-05 2003-12-22 Institute Of Medicinal Molecular Design, Inc. Inhibitors against the activation of ap-1 and nfat
EA011707B1 (ru) * 2002-06-11 2009-04-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения нейродегенеративных заболеваний
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
WO2007047863A2 (en) 2005-10-19 2007-04-26 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
DK2035001T3 (da) 2006-06-12 2012-02-27 Teva Pharma Stabile laquinimod-tilberedninger
WO2008113006A1 (en) * 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
PT2682120T (pt) 2007-12-20 2016-11-07 Teva Pharma Preparações de laquinimod estáveis
CN104311486A (zh) 2008-09-03 2015-01-28 泰华制药工业有限公司 2-羰基-1,2-二氢喹啉免疫功能调节剂
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
PL2458992T3 (pl) 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
ME02495B (me) 2009-08-10 2017-02-20 Teva Pharma Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
AU2011223697B2 (en) 2010-03-03 2016-07-14 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
SG183512A1 (en) 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
SG10201505236YA (en) 2010-07-09 2015-08-28 Teva Pharma Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
BR112013004690A2 (pt) * 2010-08-27 2016-05-10 Gruenenthal Gmbh 2-oxo-e 2-tioxo-di-hidroquinolina-3-carboxamidas substituídas como moduladores kcnq2/3
KR20130065728A (ko) * 2010-10-14 2013-06-19 임뮤나르 에이비 Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
US8889627B2 (en) 2011-10-12 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
CA2863409A1 (en) 2012-02-16 2013-08-22 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
JP5868839B2 (ja) 2012-12-27 2016-02-24 三菱重工業株式会社 チャー払出管
JP2016514162A (ja) 2013-03-14 2016-05-19 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶およびその製造のための改善された方法
EA201692180A1 (ru) 2014-04-29 2017-08-31 Тева Фармасьютикал Индастриз Лтд. Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
CN108358842A (zh) * 2014-08-28 2018-08-03 杭州普晒医药科技有限公司 他喹莫德的晶型及其制备方法、其药物组合物和用途
KR102533033B1 (ko) 2014-09-23 2023-05-15 액티브 바이오테크 에이비 다발성 골수종의 치료에 사용하기 위한 퀴놀린 카르복사미드
KR102525805B1 (ko) 2014-11-19 2023-04-25 액티브 바이오테크 에이비 백혈병 치료용 퀴놀린 카르복사미드
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
WO2018105943A1 (ko) * 2016-12-07 2018-06-14 순천향대학교 산학협력단 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물
EP4114368A1 (en) 2020-03-03 2023-01-11 Active Biotech AB Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
JP2023535021A (ja) 2020-07-23 2023-08-15 イラスマス・ユニバーシティ・メディカル・センター・ロッテルダム 骨髄増殖性腫瘍における新規治療用標的としてのｓ１００タンパク質
MX2023008016A (es) 2021-01-18 2023-07-13 Active Biotech Ab Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico.
CA3218977A1 (en) 2021-05-25 2022-12-01 Hans Wannman A plurality of tasquinimod particles and use thereof
EP4363404A1 (en) 2021-07-02 2024-05-08 Active Biotech AB A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0059698A1 (en) * 1981-03-03 1982-09-08 Ab Leo Heterocyclic carboxamides, compositions containing such compounds, processes for their preparation and methods of treatment therewith
WO1992018483A1 (en) * 1991-04-22 1992-10-29 Fujisawa Pharmaceutical Co., Ltd. Quinoline derivatives
WO1993006829A1 (en) * 1991-10-09 1993-04-15 Kabi Pharmacia Ab New use of substituted quinoline carboxamide
WO1993019756A1 (en) * 1992-04-06 1993-10-14 Kabi Pharmacia Ab The use of quinoline-3-carboxamide compounds for treatment of diabetes
WO1995024195A1 (en) * 1994-03-10 1995-09-14 Pharmacia & Upjohn Ab New use of quinoline-3-carboxamide compounds
WO1995024196A1 (en) * 1994-03-10 1995-09-14 Pharmacia & Upjohn Ab New use of quinoline-3-carboxamide compounds
WO1995024395A1 (en) * 1994-03-07 1995-09-14 Fujisawa Pharmaceutical Co., Ltd. Quinoline derivatives as immunomodulators
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07224040A (ja) * 1994-02-07 1995-08-22 Fujisawa Pharmaceut Co Ltd キノリン誘導体

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0059698A1 (en) * 1981-03-03 1982-09-08 Ab Leo Heterocyclic carboxamides, compositions containing such compounds, processes for their preparation and methods of treatment therewith
WO1992018483A1 (en) * 1991-04-22 1992-10-29 Fujisawa Pharmaceutical Co., Ltd. Quinoline derivatives
WO1993006829A1 (en) * 1991-10-09 1993-04-15 Kabi Pharmacia Ab New use of substituted quinoline carboxamide
WO1993019756A1 (en) * 1992-04-06 1993-10-14 Kabi Pharmacia Ab The use of quinoline-3-carboxamide compounds for treatment of diabetes
WO1995024395A1 (en) * 1994-03-07 1995-09-14 Fujisawa Pharmaceutical Co., Ltd. Quinoline derivatives as immunomodulators
WO1995024195A1 (en) * 1994-03-10 1995-09-14 Pharmacia & Upjohn Ab New use of quinoline-3-carboxamide compounds
WO1995024196A1 (en) * 1994-03-10 1995-09-14 Pharmacia & Upjohn Ab New use of quinoline-3-carboxamide compounds
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives

Also Published As

Publication number Publication date
HRP20010039A2 (en) 2001-12-31
RU2213733C2 (ru) 2003-10-10
CZ300229B6 (cs) 2009-03-25
AU751103B2 (en) 2002-08-08
UA64791C2 (en) 2004-03-15
PL199783B1 (pl) 2008-10-31
MEP57408A (en) 2011-05-10
AU4950499A (en) 2000-02-07
KR100516382B1 (ko) 2005-09-26
BR9912109B1 (pt) 2012-08-21
DE69911415T2 (de) 2004-07-08
CA2336968A1 (en) 2000-01-27
IS5775A (is) 2000-12-18
EP1095021A1 (en) 2001-05-02
HUP0103224A3 (en) 2002-11-28
NZ508923A (en) 2002-09-27
CN1157378C (zh) 2004-07-14
YU1501A (sh) 2003-10-31
ATE250036T1 (de) 2003-10-15
ME00374B (me) 2011-05-10
IS2208B (is) 2007-02-15
WO2000003991A1 (en) 2000-01-27
DK1095021T3 (da) 2003-11-24
OA11906A (en) 2006-04-10
IL140346A0 (en) 2002-02-10
ID27423A (id) 2001-04-05
PT1095021E (pt) 2003-12-31
ZA200007593B (en) 2001-07-09
NO20010211L (no) 2001-03-15
RS50128B (sr) 2009-03-25
BR9912109A (pt) 2001-05-02
HK1035715A1 (en) 2001-12-07
CN1309641A (zh) 2001-08-22
HU229427B1 (en) 2013-12-30
EE200100010A (et) 2002-06-17
EE04673B1 (et) 2006-08-15
EP1095021B1 (en) 2003-09-17
CZ200194A3 (en) 2001-05-16
NO317601B1 (no) 2004-11-22
AP1366A (en) 2005-01-26
NO20010211D0 (no) 2001-01-12
IL140346A (en) 2006-07-05
JP4045070B2 (ja) 2008-02-13
TR200100087T2 (tr) 2001-06-21
SE9802549D0 (sv) 1998-07-15
ES2205854T3 (es) 2004-05-01
PL345388A1 (en) 2001-12-17
AP2001002041A0 (en) 2001-03-31
JP2002520395A (ja) 2002-07-09
KR20010053115A (ko) 2001-06-25
DE69911415D1 (de) 2003-10-23
HUP0103224A2 (hu) 2002-01-28
CA2336968C (en) 2005-08-30

Similar Documents

Publication Publication Date Title
HRP20010039B1 (en) Quinoline derivatives
HRP20000726B1 (en) Quinoline derivatives
CA2298033A1 (en) Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
GR3036887T3 (en) Meta-substituted phenylene sulphonamide derivatives
CA2205274A1 (en) Novel 2,3 disubstituted-(5,6)-heteroarylfused-pyrimidine-4-ones
YU35697A (en) Substituted 6,6-hetero-bicyclic derivatives
RS51019B (sr) Lekovi za lečenje malignih tumora
DE69329727D1 (de) Neue imidazol derivate, ihre herstellung und therapeutische verwendung
NZ518296A (en) N-phenyl-1,2-dihydro-2-oxo-quinoline-3-carboxamide derivatives and their use in the treatment of breast and prostatic cancer
NZ503912A (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists
ES2122258T3 (es) 4-azaesteroides 15 sustituidos.
IE872773L (en) 4,5-DIHYDRO and 4,5,6,7-TETRAHYDROPYRAZOLO£1.5-a|PYRIMIDINES
NO20001585L (no) Orale sammensetninger av levosimendan
SE8503415L (sv) Nya isoindolinylalkylpiperaziner och farmaceutiska kompositioner innehallande desamma
MX9204179A (es) Derivados de imidazo(2,1-b)benzotiazola-3-acetamida, su preparacion y su aplicacion en terapeutica.
DE69719974D1 (de) Chinolinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AU2001261707A1 (en) Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives
DE69418478T2 (de) Herbizide pyridinverbindungen
JPS57163368A (en) 4-aryloxy-1,2,3,4-tetrahydroisoquinoline and intermediate
DK0625982T3 (da) 4-Oxo- og 4H-imidazo(5,1-c)(1,4)benzoxaziner anvendelige som benzodiazepinreceptor-bindemidler
RS50791B (sr) Farmaceutske kombinacije zasnovane na derivatima piridoindolona
EP1319658A4 (en) IMIDAZOLE DERIVATIVES OR THEIR SALTS
YU200791A (sh) Trifluorometil 1-karba (1-detia) cefemi
FI961793A0 (fi) Muistia parantavina aineina käyttökelpoiset 3-aryyli-4-alkyyli- ja 4,5-dialkyyli 4H-1,2,4-triatsolit
FI914138A (fi) Laekemedel, vilka innehaoller substituerade 2-cyklohexenderivat och deras anvaendning vid vaord av sjukdomar.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20170614

Year of fee payment: 19

PBON Lapse due to non-payment of renewal fee

Effective date: 20180714